Reports
Sale
Global Wegener’s Granulomatosis Treatment Market Share, Size: By Diagnosis Method: Lab Test, Imaging tests, Biopsy; By Drug Classification: Medication, Plasma Exchange; By Route of Administration: Oral, Intravenous, Others; By Therapeutic Channel: Public, Private; Regional Analysis; Supplier Landscape; 2024-2032
Global Wegener’s Granulomatosis Treatment Market Outlook
The Wegener’s granulomatosis treatment market is estimated grow at a CAGR of 5.90% in the forecast period of 2024-2032. The market is expected to grow owing to the increasing prevalence of Wegener’s granulomatosis and improved governmental and private actions to increase understanding about the right diagnosis and treatment of such a rare ailment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Wegener’s Granulomatosis Insights
GPA, or granulomatosis with polyangiitis (Wegener's), is a rare blood vessel disease. It is a potentially fatal autoimmune illness with an unclear cause. Since the inflammation in the blood vessel prevents optimal blood flow, the cells do not receive the oxygen they require. This results in tissue damage known as granulomatous inflammation. A granuloma is a form of cellular inflammation that is typically seen in biopsies of damaged organs. The traditional clinical triad includes necrotizing granulomatous inflammation of the upper and/or lower respiratory tract, necrotizing glomerulonephritis, and an autoimmune necrotizing systemic vasculitis that primarily affects tiny arteries.
This rare condition is believed to impact 3 people out of every 100,000. It has an equal impact on males and women. GPA can happen at any age, although it is most common between the ages of 40 and 65. It is uncommon in children.
There is no single exam for determining GPA. Many factors contribute to GPA diagnosis, including symptoms, physical examination, blood testing, and imaging procedures like X-rays, CT scans, or MRI.
Active GPA produces inflammation in the blood vessels and organs. Chronic inflammation in blood arteries or organs can lead to organ failure. Without therapy, GPA can rapidly develop, potentially leading to life-threatening kidney or lung failure.
Those with active severe disease are frequently given a glucocorticoid (steroid) medicine, such as Prednisone in combination with Cyclophosphamide (Cytoxan), a chemotherapy treatment. Prednisone is given at a high dose and progressively tapered off over a period of weeks to months. Cyclophosphamide is administered orally or by injection for three to six months. Those who improve are subsequently shifted to another medicine for 2 or more years, such as Methotrexate (Rheumatrex, Trexall) or Azathioprine (Imuran, Azasan). Prednisone and Methotrexate may be used to treat those with less active illness.
According to the Wegener’s granulomatosis treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis
- Lab Test
- Blood Test
- Urine Test
- Imaging Tests
- Chest X-rays
- CT Scan
- MRI
- Biopsy
Market Breakup by Drug
- Medication
- Steroids
- Immunosuppressant
- Others
- Plasma Exchange
Wegener’s Granulomatosis Treatment Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
Market Breakup by Therapeutic Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Wegener’s Granulomatosis Epidemiology
The global prevalence is predicted to be between 1/6,400 and 42,000, with an annual incidence of 1/84,000 to 475,000. There is geographic and/or ethnic variation, with colder places and Caucasians having a higher occurrence. Childhood-onset disease has a female predominance, whereas adult-onset disease has a little male predominance.
Wegener’s Granulomatosis Treatment Market Drivers
The North American region is likely to lead the market throughout the projection period due to the higher incidence rate of Wegener’s granulomatosis. 3 per 100,000 people are affected by Wegener’s granulomatosis.
Due to high prevalence rates, improved healthcare infrastructure and amenities, increased government activities, rising disposable income in this region, expansion of the healthcare system, and increasing approval rates for additional novel medications, the Asia Pacific region is expected to grow at the fastest rate. The market expansion is being driven by the region’s rapidly expanding healthcare infrastructure, particularly in China and India, and the region’s increased awareness of rare disease treatment.
Clinical studies and increased R&D spending have allowed for the introduction of novel medicine molecules to the market. The companies are developing potential drug options to improve the treatment of GPA.
Additionally, enhanced governmental and private actions to increase information regarding correct diagnosis and treatment of such a rare ailment, technology improvements, increased public health awareness, and favourable reimbursement rules will boost the market expansion.
Therapeutic Trends and Innovation
The increased use of monoclonal antibodies and recent advances in systemic treatment of Wegener's granulomatosis, including the introduction of investigational immunosuppressive drugs, such as Etanercept, Leflunomide, and Deoxyspergualin, are expected to shift the conventional treatment paradigm.
ChemoCentryx, Inc. gained USFDA approval for TAVNEOS (avacopan) in October 2021. It is used to treat adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), specifical Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is an orally administered selective complement 5a receptor inhibitor used in conjunction with conventional therapy.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the Wegener’s granulomatosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Sonoma Pharmaceuticals, Inc.
- GSK plc
- Halozyme Therapeutics, Inc
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
- Aprogen, Inc.
- Amgen, Inc.
- Epirus Biopharmaceuticals, Inc.
- Pfizer Inc.
- Novartis AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Drug Classification |
|
| Breakup by Route of Administration |
|
| Breakup by Therapeutic Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Wegener's Granulomatosis Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation
6.1 Emerging Therapies and Clinical trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Wegener's Granulomatosis Treatment Market
8.1 Global Wegener's Granulomatosis Treatment Market Overview
8.2 Global Wegener's Granulomatosis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Historical Wegener's Granulomatosis Treatment Market Historical Value (2017-2023)
8.2.1.2 Global Forecast Wegener's Granulomatosis Treatment Market Forecast Value (2024-2032)
8.2.2 Global Wegener's Granulomatosis Treatment Market by Diagnosis Method
8.2.2.1 Market Overview
8.2.2.1.1 Lab Test
8.2.2.1.1.1 Blood Test
8.2.2.1.1.2 Urine Test
8.2.2.1.2 Imaging tests
8.2.2.1.2.1 Chest X-rays
8.2.2.1.2.2 CT Scan
8.2.2.1.2.3 MRI
8.2.2.1.3 Biopsy
8.2.3 Global Wegener's Granulomatosis Treatment Market by Drug Classification
8.2.3.1 Market Overview
8.2.3.1.1 Medication
8.2.3.1.1.1 Steroids
8.2.3.1.1.2 Immunosuppressant
8.2.3.1.1.3 Others
8.2.3.1.2 Plasma Exchange
8.2.4 Global Wegener’s Granulomatosis Treatment Market by Route of Administration
8.2.4.1 Market Overview
8.2.4.1.1 Oral
8.2.4.1.2 Intravenous
8.2.4.1.3 Others
8.3 Global Wegener's Granulomatosis Treatment Market by Therapeutic Channel
8.3.1 Market Overview
8.3.1.1 Public
8.3.1.2 Private
8.4 Global Wegener's Granulomatosis Treatment Market by Region
8.4.1 Market Overview
8.4.1.1 North America
8.4.1.2 Europe
8.4.1.3 Asia Pacific
8.4.1.4 Latin America
8.4.1.5 Middle East and Africa
9 North America Wegener’s Granulomatosis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Wegener’s Granulomatosis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Wegener’s Granulomatosis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Wegener’s Granulomatosis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Wegener’s Granulomatosis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Wegener's Granulomatosis Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sonoma Pharmaceuticals, Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 GSK plc
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Halozyme Therapeutics, Inc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Sun Pharmaceutical Industries
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Teva Pharmaceutical Industries
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Aprogen, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Amgen, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Epirus Biopharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Pfizer Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Novartis AG
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Wegener's Granulomatosis Treatment Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is likely to grow at a CAGR of 5.90% during the forecast period of 2024-2032.
The market is expected to witness significant growth owing to the increasing prevalence of Wegener’s granulomatosis, improved actions to increase understanding about the right diagnosis and treatment of such a rare ailment, technology improvements, an increase in public health awareness, and favourable reimbursement regulations.
North America is the dominating region in the market owing to the rising demand for the market.
Sonoma Pharmaceuticals, Inc., GSK plc, Halozyme Therapeutics, Inc, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Aprogen, Inc., Amgen, Inc., Epirus Biopharmaceuticals, Inc., Pfizer Inc., and Novartis AG, among others, are the leading companies in the market.
Yes, Wegener’s is an autoimmune disease. There is currently no cure but early diagnosis and adequate treatment can put the disease into relapse, allowing many patients to live full, productive lives. GPA, if left untreated, can cause possibly fatal organ damage or failure.
A tissue biopsy is required to confirm the diagnosis of Wegener granulomatosis. Biopsies of the upper respiratory tract reveal acute and chronic inflammation with granulomatous alterations. Kidney biopsies generally reveal segmental necrotizing pauci-immune glomerulonephritis, which is frequently angiocentric.
Pulmonologist (lung specialist); an otolaryngologist (ear, nose, and throat specialist); a nephrologist (kidney specialist); or a bone and joint specialist (rheumatologist) should be consulted to manage Wegener’s granulomatosis.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER